1. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy 
Fernand Labrie, MD, PhD, Leonard Derogatis, PhD, David F. Archer, MD, William Koltun, MD, Andrée Vachon, MD, Douglas Young, MD, Louise Frenette, MD, David Portman, MD, Marlene Montesino, MD, Isabelle Côté, BSc, Julie Parent, PhD, Lyne Lavoie, MSc, Adam Beauregard, BSc, MBA, Céline Martel, PhD, Mario Vaillancourt, BSc, MBA, John Balser, PhD, Érick Moyneur, BSc, MA 
The Journal of Sexual Medicine 
Volume 12, Issue 12, Pages (December 2015)
DOI: /jsm.13045
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

2. Figure 1
Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the desire domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo.
The Journal of Sexual Medicine  , DOI: ( /jsm.13045)
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

3. Figure 2
Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the arousal domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo.
The Journal of Sexual Medicine  , DOI: ( /jsm.13045)
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

4. Figure 3
Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the lubrication domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo.
The Journal of Sexual Medicine  , DOI: ( /jsm.13045)
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

5. Figure 4
Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the orgasm domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P value for the prasterone group is comparison with placebo.
The Journal of Sexual Medicine  , DOI: ( /jsm.13045)
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

6. Figure 5
Effect of daily intravaginal application of 0.0% (n=149) and 0.50% (n=300) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the satisfaction domain of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P values for the prasterone group is comparison with placebo at all time intervals. *In this domain, few women were excluded since they have not answered one and/or two questions related to sexual activity with a partner.
The Journal of Sexual Medicine  , DOI: ( /jsm.13045)
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

7. Figure 6
Effect of daily intravaginal application of 0.0% (n=157) and 0.50% (n=325) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the pain domain of Female Sexual Function Index (FSFI) in post-menopausal women. Data are expressed as means±standard error of the mean (SEM); the P values for the prasterone group is comparison with placebo at all time intervals.
The Journal of Sexual Medicine  , DOI: ( /jsm.13045)
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions

8. Figure 7
Effect of daily intravaginal application of 0.0% (n=149) and 0.50% (n=300) dehydroepiandrosterone (DHEA; prasterone) for 6 and 12 weeks on the total score of Female Sexual Function Index (FSFI) in postmenopausal women. Data are expressed as means±standard error of the mean (SEM); the P values for the prasterone group is comparison with placebo at all time intervals. *Few women were excluded from the total score as they have not answered some questions in the satisfaction domain.
The Journal of Sexual Medicine  , DOI: ( /jsm.13045)
Copyright © 2015 International Society for Sexual Medicine Terms and Conditions